Clinical Trials Browser

Phase 1/2 × Carcinoma, Hepatocellular × PR-104 × Clear all

NCT00862082 2013-08-23

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Phase 1/2 Terminated

14 enrolled 15 charts

Gastrointestinal

Carcinoma, Hepatocellular